FGF-23 and sFRP-4 in Chronic Kidney Disease and Post-Renal Transplantation
Nephron Physiology · 14.08.2006 · 104 (1) · p23-p32
DOI: 10.1159/000093277 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephron Physiology, online erschienen am 14.08.2006. Verfasst von Sangeeta Pande und 8 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Washington University School of Medicine, St. Louis, Mo. 63110, USA. Hauptthemen laut MEDLINE: Kidney Transplantation. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Background
The phosphatonins fibroblast growth factor-23 (FGF-23) and FRP-4 are inhibitors of tubular phosphate reabsorption that may play a role in the hyperphosphatemia associated with chronic kidney disease (CKD) or in the hypophosphatemia associated with renal transplants.
Methods
Plasma FGF-23, FRP-4, phosphorus and parathyroid hormone were measured in patients at all stages of CKD. Phosphate regulation of FGF-23 and secreted frizzled related protein-4 (sFRP-4) was examined in end-stage renal disease patients in the presence and absence of therapeutic phosphate binder usage. In renal transplant patients, plasma FGF-23, sFRP-4 and phosphorus concentrations were determined before and 4–5 days after transplantation.
Results
Plasma FGF-23 correlated with creatinine clearance (r2 = –0.584, p < 0.0001) and plasma phosphorus (r2 = 0.347, p < 0.001) in CKD patients and with plasma phosphorus (r2 = 0.448, p < 0.001) in end-stage renal disease patients. Phosphate binder withdrawal increased FGF-23 levels. In kidney transplant patients, dramatic decreases in FGF-23 (–88.8 ± 5.4%) and phosphorus (–64 ± 10.2%) were observed by 4–5 days post-transplantation. In patients with post-transplant hypophosphatemia, FGF-23 levels correlated inversely with plasma phosphorus (r2 = 0.661, p < 0.05). sFRP-4 levels did not change with creatinine clearance or hyperphosphatemia in CKD or end-stage renal disease patients, and no relation was noted between post-transplant sFRP-4 levels and hypophosphatemia.
Conclusions
In CKD, FGF-23 levels rose with decreasing creatinine clearance rates and increasing plasma phosphorus levels, and rapidly decreased post-transplantation suggesting FGF-23 is cleared by the kidney. Residual FGF-23 may contribute to the hypophosphatemia in post-transplant patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Renal Division, Washington University School of Medicine, St. Louis, Mo. 63110, USA.
Förderung
- NIDDK NIH HHS
Zitieren
APA
Pande, S., Ritter, C. S., Rothstein, M., Wiesen, K., Vassiliadis, J., Kumar, R., Schiavi, S. C., Slatapolsky, E., & Brown, A. J. (2006). FGF-23 and sFRP-4 in Chronic Kidney Disease and Post-Renal Transplantation. Nephron Physiology, 104(1), p23-p32. https://doi.org/10.1159/000093277
Vancouver
Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R, et al. FGF-23 and sFRP-4 in Chronic Kidney Disease and Post-Renal Transplantation. Nephron Physiology. 2006;104(1):p23-p32. doi:10.1159/000093277
BibTeX
@article{Pande2006,
author = {Pande, Sangeeta and Ritter, Cynthia S and Rothstein, Marcos and Wiesen, Karen and Vassiliadis, John and Kumar, Rajiv and Schiavi, Susan C and Slatapolsky, Eduardo and Brown, Alex J},
title = {FGF-23 and sFRP-4 in Chronic Kidney Disease and Post-Renal Transplantation},
journal = {Nephron Physiology},
year = {2006},
volume = {104},
number = {1},
pages = {p23--p32},
doi = {10.1159/000093277}
}
EUVIMED